优化串联CD19/CD20 CAR工程化T细胞治疗难治/复发性B细胞淋巴瘤
本研究设计串联CAR(TanCAR)并开展开放标签单臂1/2a期试验(NCT03097770),33例难治/复发性非霍奇金淋巴瘤患者入组,28例接受TanCAR7 T细胞输注。主要目的为评估安全性与耐受性,细胞因子释放综合征发生14例(50%),总缓解率79%(95%CI 60-92%),完全缓解率71%,12个月无进展生存率64%(95%CI 43-79%)。
要点
- TanCAR7 T细胞可双靶向CD19和CD20,并形成稳定免疫突触。
- 细胞因子释放综合征发生14例(50%),其中1-2级36%、3级14%。
- 总缓解率79%(95%CI 60-92%),完全缓解率71%,12个月无进展生存率64%(95%CI 43-79%)。
核心结论
- TanCAR7 T细胞在难治/复发性非霍奇金淋巴瘤患者中引发强效且持久的抗肿瘤反应,但未出现3级或以上CAR T细胞相关脑病综合征。
研究设计与样本
- 开放标签单臂1/2a期试验(NCT03097770),入组33例难治/复发性非霍奇金淋巴瘤患者,28例在预处理化疗后接受TanCAR7 T细胞输注。
- 主要目的为评估TanCAR7 T细胞的安全性与耐受性,疗效、无进展生存和总生存为次要目的。
主要发现
- 细胞因子释放综合征发生于14例患者(50%):36%为1级或2级,14%为3级。
- 任何患者中均未确认3级或以上CAR T细胞相关脑病综合征(CRES)病例。
- 1例患者死于治疗相关的严重肺部感染。
- 总缓解率为79%(95%置信区间[CI],60-92%),完全缓解率为71%。
- 12个月无进展生存率为64%(95%CI,43-79%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T cells targeting CD19 have achieved breakthroughs in the treatment of hematological malignancies, such as relapsed/refractory non-Hodgkin lymphoma (r/rNHL); however, high rates of treatment failure and recurrence after CAR T-cell therapy are considerable obstacles to overcome. In this study, we designed a series of tandem CARs (TanCARs) and found that TanCAR7 T cells showed dual antigen targeting of CD19 and CD20, as well as formed superior and stable immunological synapse (IS) structures, which may be related to their robust antitumor activity. In an open-label single-arm phase 1/2a trial (NCT03097770), we enrolled 33 patients with r/rNHL; 28 patients received an infusion after conditioning chemotherapy. The primary objective was to evaluate the safety and tolerability of TanCAR7 T cells. Efficacy, progression-free survival, and overall survival were evaluated as secondary objectives. Cytokine release syndrome occurred in 14 patients (50%): 36% had grade 1 or 2 and 14% had grade 3. No cases of CAR T-cell-related encephalopathy syndrome (CRES) of grade 3 or higher were confirmed in any patient. One patient died from a treatment-associated severe pulmonary infection. The overall response rate was 79% (95% confidence interval [CI], 60-92%), and the complete response rate was 71%. The progression-free survival rate at 12 months was 64% (95% CI, 43-79%). In this study, TanCAR7 T cells elicited a potent and durable antitumor response, but not grade 3 or higher CRES, in patients with r/rNHL.
引用
- Tong C, Zhang Y, Liu Y, et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood. 2020. PMID: 32556247. doi:10.1182/blood.2020005278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。